Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients

Annals of Hepatology

Volumn 12, Issue 1, 2013, Pages 44-53

  Attallah, Abdelfattah M ^a   Abdallah, Sanaa O ^b   Attallah, Ahmed A ^a   Omran, Mohamed M ^a   Farid, Khaled ^c,d   Nasif, Wesam A ^e   Shiha, Gamal E ^c   Abdel Aziz, Abdel Aziz F ^f   Rasafy, Nancy ^a   Shaker, Yehia M ^g  

^a Biotechnology Research Centre   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d HELWAN UNIVERSITY   (Egypt)

^e MENOUFIA UNIVERSITY   (Egypt)

^f MANSOURA UNIVERSITY   (Egypt)

^g NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Advanced liver fibrosis; Blood markers; Discriminant analysis; Noninvasive; Significant liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FIBRONECTIN; BIOLOGICAL MARKER; SERUM ALBUMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAVIR SCORING SYSTEM; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; VALIDATION STUDY; BLOOD; DISCRIMINANT ANALYSIS; ECHOGRAPHY; EXTRACELLULAR MATRIX; LARGE CORE NEEDLE BIOPSY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY, LARGE-CORE NEEDLE; DISCRIMINANT ANALYSIS; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

MLCS; MLOWN;

EID: 84878698855     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31384-5     Document Type: Article

References (43)

1. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.
2. Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatol 2002; 36:1039.
3. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. WJ Gastroenterol 2010; 16: 4784-91.
4. Straub BK, Schirmacher P. Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 197-202.
5. Chang DY, Shin EC. Immune-based therapy for chronic hepatitis C. J Leukoc Biol 2009; 86: 33-9.
6. de Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. Vox Sang 2009; 97: 1-12.
7. Yeshua H, Oren R. Non invasive assessment of liver fibrosis. Ann Transplant 2008; 13: 5-11.
8. Abenavoli L, Addolorato G, Riccardi L, Gasbarrini A, Gasbarrini G, Rapaccini GL. Elastography assessment in patients with chronic HCV infection. Int J Clin Pract 2008; 62: 1108-12.
9. Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008; 38: 762-9.
10. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. WJ Gastroenterol 2006; 12: 3682-94.
11. Han KH, Yoon KT. New diagnostic method for liver fibrosis and cirrhosis. Lntervirol 2008; 51: 11-6.
12. Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 73-9.
13. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-90.
14. Helvaci M, Ozkaya B, Ozbal E, Ozinel S, Yaprak I. Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection. Pediatr Int 1999; 41: 270-3.
15. Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol 2010; 45: 349-56.
16. Attallah AM, Zahran F, Ismail H, Omran MM, El-Dosoky I, Shiha GE. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay lmmunochem 2007; 28: 331-42.
17. Attallah AM, Ismail H, Shiha GE, Abou-Dobara MI, El-Sherbiny RE, El-Dosoky I. Immunochemical identification and partial characterization of a native hepatitis C viral nonstructural 4 antigen in sera of HCV infected patients. Clin Chim Acta 2008; 388: 115-22.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOS VIRC groups. Lancet 1997; 349: 825-32.
19. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38: 518-26.
20. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-9.
21. Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 1983; 258: 4641-7.
22. Benyon D, Arthur MJP. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001; 21: 373-84.
23. Junge J, Horn T, Christoffersen P. The occurrence and significance of fibronectin in livers from chronic alcoholics. An immunohistochemical study of early alcoholic liver injury. APMIS 1988; 96: 56-61.
24. Tormihira M. Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases. Fukuoka lgaku Zasshi 1991; 82: 21-30.
25. Simon K, Zalewska M, Gladysz A, Rotter K, Piszko P, Glowacki A. A Plasma fibronectin in chronic liver diseasemarker of fibrosis? Przegl Lek 1995; 52: 129-32.
26. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 1918-22.
27. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrornbocytopenia. J Clin Invest 1966; 45: 645-57.
28. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatol 1985; 5: 367-75.
29. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008; 9: 1092-101.
30. Stolz A, Kaplowitz N. Biochemical tests for liver disease. In: Zakim D, Boyer TD (eds.). Hepatology. A Textbook of Liver Disease, Vol. 1. Philadelphia PA: Saunders; 1990, p. 637-67.
31. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
32. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E, Gentile I et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001; 47: 1696-700.
33. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49: 450-4.
34. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, et al. FIBROSTIC study group: Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21.
35. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.
36. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007; 120: 280.
37. Wong VW, Chan HL. Transient elastography. J Gastroenterol Hepatol 2010; 25: 1726-31.
38. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 2011; 5: 625-34.
39. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatol 2011; 53: 2107-10.
40. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46: 628-34.
41. Takemoto R, Nakamuta M, Aoyagi Y, et al. Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Dig Dis 2009; 10: 145-8.
42. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9: 43-51.
43. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatol 2004; 39: 1147-71.